This article is more than 5 years old. Information may no longer be current.

Trefoil Therapeutics secures $5.2 million in financing

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Trefoil Therapeutics has raised $5.2 million in Series 1 financing, led by Hatteras Venture Partners, according to a company press release.

The funding, along with a collaborative research agreement with the National Institutes of Health National Center for Advancing Translational Sciences Therapeutics for Rare and Neglected Diseases, will go toward research to support an investigational new drug filing for TTHX1114, the release said.

TTHX1114 is currently being developed by Trefoil as the first therapeutic application to treat Fuchs’ endothelial corneal dystrophy.